• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

    4/13/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email

    Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic value

    NEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.  The addition reflects Dario's continued alignment of board composition with its next phase of commercial scaling.

    DarioHealth Corp. Logo (PRNewsfoto/DarioHealth Corp.)

    Mr. Palumbo brings more than 40 years of healthcare operating experience across early-stage ventures and Fortune 100 enterprises.  His substantial background includes senior leadership roles at AmerisourceBergen Corporation (now Cencora, Inc.), where he led the provider business unit and expanded consulting and technology capabilities into a multibillion-dollar platform serving health systems nationwide, as well as Chief Operating Officer of Allscripts Healthcare Solutions, Inc. (now Veradigm, Inc.) and leadership positions at Shared Medical Systems Corporation (Siemens Aktiengesellschaft).

    "John's appointment is highly intentional and strategically valuable," stated Dario's Chief Executive Officer, Erez Raphael.  "As we transition from demonstrating the strength of our distribution model to scaling it efficiently through channel partnerships, we are adding leaders to our board who have done exactly that.  John brings a rare combination of strategic insight, operational discipline and deep industry relationships that will directly support our growth trajectory. He has been at the center of some of healthcare's most consequential strategic transactions and organizational transformations, and his relationships with senior decision-makers across the payer, provider and health services landscape will be invaluable as we continue to build and scale.  We are increasingly confident that the market will come to fully reflect the value we have built – and we are not standing still while that recognition develops."

    Mr. Palumbo has guided organizations through transformative growth, including supporting two companies through IPOs and leading large-scale operational and commercial transformations.  His experience is particularly relevant to Dario's evolution toward a more capital-efficient, partner-led go-to-market strategy. He brings deep familiarity with the care delivery ecosystem, including the health systems, payers and provider services organizations that are shaping its consolidation – adding a dimension of strategic reach that directly complements Dario's next phase.

    In addition to his operating capabilities, Mr. Palumbo is actively engaged in the digital health ecosystem. He currently serves on the boards of PM Pediatrics Management Group, LLC, Lucid Diagnostics Inc., ivWatch, LLC and Qless, Inc., and chairs the advisory board of Brado Cuneo Nollau, LLC, an AI-driven engagement platform serving health systems.

    "Dario is at a compelling inflection point," said Mr. Palumbo. "The Company has built a differentiated, integrated solution with strong engagement which is delivering proven economic and clinical outcomes.  The opportunity now is to scale that value through the right commercial channels and ensure the Company captures the full strategic opportunity its platform represents.  I look forward to working closely with management to help accelerate both our commercial momentum and the value creation this platform deserves."

    About DarioHealth Corp. (NASDAQ:DRIO)



    DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

    Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

    Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. 

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expectation that Mr. Palumbo's experience will directly support its growth trajectory, its belief that adding Mr. Palumbo as a member of the Board will be instrumental in guiding Dario's continued expansion within the payer, provider and health services markets and its expectation that Mr. Palumbo's appointment will accelerate Dario's commercial partnerships and position the Company to realize its full strategic value. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    DarioHealth Corporate Contacts

    Michael Lipari

    SVP Corporate Development

    [email protected]

    +1-201-785-6310

    Rob Halpern

    SVP Marketing

    [email protected] 

    Logo - https://mma.prnewswire.com/media/2866807/5909333/Dario_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dario-appoints-veteran-healthcare-executive-john-r-palumbo-to-board-of-directors-to-support-accelerated-commercial-scaling-302738787.html

    SOURCE DarioHealth Corp.

    Get the next $DRIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    SEC Filings

    View All

    DarioHealth Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - DarioHealth Corp. (0001533998) (Filer)

    4/13/26 8:21:08 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by DarioHealth Corp.

    424B5 - DarioHealth Corp. (0001533998) (Filer)

    3/30/26 6:14:55 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - DarioHealth Corp. (0001533998) (Filer)

    3/30/26 5:31:40 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

    Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic valueNEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.  The addition reflects Dario's continued alignment of board composition with its next phase of commercial scaling. Mr. Palumbo brings more than 40 ye

    4/13/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR")  set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-

    3/19/26 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026

    Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, March 11, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, March 19th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: Thursday, March19th, 2026, 8:30 a.m. Eastern TimeDial-in Numb

    3/11/26 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles bought $21,200 worth of shares (40,000 units at $0.53), increasing direct ownership by 73% to 95,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    8/27/25 4:30:59 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    11/14/24 4:15:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/12/24 4:37:42 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Palumbo John R

    3 - DarioHealth Corp. (0001533998) (Issuer)

    4/13/26 4:05:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    President and CCO Nelson Steven Charles was granted 30,000 shares, increasing direct ownership by 632% to 34,750 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:04:08 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Stern Adam K was granted 20,000 shares, increasing direct ownership by 206% to 29,717 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:03:10 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth downgraded by TD Cowen with a new price target

    TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

    1/29/25 7:36:04 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth upgraded by Alliance Global Partners with a new price target

    Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

    5/13/22 9:01:42 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Aegis Capital reiterated coverage on DarioHealth with a new price target

    Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

    1/26/22 10:35:44 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Financials

    Live finance-specific insights

    View All

    DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR")  set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-

    3/19/26 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026

    Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, March 11, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, March 19th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: Thursday, March19th, 2026, 8:30 a.m. Eastern TimeDial-in Numb

    3/11/26 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Reports Third Quarter 2025 Financial and Operating Results

    Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025 Targeting $12.4 million in new business, reflecting both committed annual recurring revenue ("CARR") and late-stage opportunities nearing completion; 2026 pipeline expanded to $69 millionExceeded 2025 goal of 40 new signed accounts for 2026 revenue, with 45 new signed accounts to date—several already contributing to 2025 results; average employer customer size nearly doubled what was projectedStrong business fundamentals in the third quarter including GAAP gross margin increase to 60%, 7 consecutive quarters of 80%+ non-GAAP gross margins on core

    11/13/25 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    10/29/24 11:45:28 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

    SC 13G/A - DarioHealth Corp. (0001533998) (Subject)

    2/14/24 4:51:40 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Leadership Updates

    Live Leadership Updates

    View All

    Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

    Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic valueNEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.  The addition reflects Dario's continued alignment of board composition with its next phase of commercial scaling. Mr. Palumbo brings more than 40 ye

    4/13/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

    Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

    2/27/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

    Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

    10/28/24 4:44:00 PM ET
    $BMY
    $DRIO
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments